Mr. Bruce Linton reports

CANOPY HEALTH INNOVATIONS FILES A SUITE OF ADDITIONAL CANNABIS-RELATED PATENTS

Canopy Health Innovations, the partly owned biopharmaceutical research and development affiliate of Canopy Growth Corp., has, alone or with its subsidiary Canopy Animal Health or through its joint venture Beckley Canopy Therapeutics, filed eight provisional U.S. patents pertaining to the delivery and application of cannabis and cannabinoid-based therapeutics in certain indications.

Specifically, the eight patent applications relate to the following:

• Fibromyalgia;
• Amyotrophic lateral sclerosis (also known as ALS, Lou Gehrig's disease);
• Anxiety and its various subgroups (in humans and animals, in conjunction with Canopy Animal Health);
• Cognitive enhancement (in humans and animals, in conjunction with Canopy Animal Health);
• Pain and various subgroups (in humans and animals, in conjunction with Canopy Animal Health);
• Opioid sparing, pain management and addiction (through Beckley Canopy Therapeutics);
• Addiction and smoking cessation (through Beckley Canopy Therapeutics);
• A platform and method for delivery of cannabis-based compositions.

In addition to updated applications relating to earlier Insomnia patent applications, this brings the total number of U.S. provisional patent filings (including Canopy Animal Health and Beckley Canopy Therapeutics) to 39.

These filings are part of a concerted plan to bring to patients and health care providers innovative medicines and health products targeting disease areas with substantial medical needs. As part of this plan, Canopy Health and its affiliates are collaborating with respected world-class academic researchers and clinicians, and working with leading research organizations and regulators in jurisdictions of interest to develop and register these breakthrough products.

"As global medical markets emerge the trend among regulators favours highly regulated and highly repeatable medical cannabis options," said Bruce Linton, chairman and chief executive officer, Canopy Growth. "Through Canopy Health's work we are bulding a body of knowledge around cannabinoid medicine that will lead to its inclusion in mainstream health care for the benefit of patients."

Canopy Health and its affiliates continue their practice of filing provisional patents in the United States, which is common in the field of intellectual property generation and protection. Patents are first filed in the United States to create a priority date and allow for future filings in other selected jurisdictions, including Canada.

Although cannabis is not presently federally legal in the United States for commercial purposes, it is still the most common "first to file" jurisdiction for intellectual property generation and protection activity pertaining to cannabis and cannabinoids.

Here's to future growth.

About Canopy Health Innovations

Canopy Health Innovations operates as an independent and private collaborator of Canopy Growth and its subsidiaries. Canopy Health is owned in part by Canopy Growth and qualified private investors. Canopy Health's business model is to engage simultaneously in numerous research areas, with a strict focus on the creation and enhancement of intellectual property, which is then retained exclusively on a first-priority basis. Canopy Growth and its subsidiaries retain an exclusive, first-priority right to license and commercialize intellectual property developed and owned by Canopy Health.

About Canopy Growth Corp.

Canopy Growth is a world-leading diversified cannabis company, offering distinct brands and curated cannabis varieties in dried, oil and capsule forms. Through its wholly owned subsidiaries, Canopy Growth operates numerous state-of-the-art production facilities with over half a million square feet of Good Manufacturing Practice-certified indoor and greenhouse production capacity, all to an unparalleled level of quality assurance procedures and testing. Canopy Growth has established partnerships with leading sector names in Canada and abroad, with interests and operations spanning four continents. The company is proudly dedicated to educating health care practitioners, providing consistent access to high-quality cannabis products, conducting robust clinical research and furthering the public's understanding of cannabis.

We seek Safe Harbor.